孟鲁司特致神经系统药品不良反应特点的分析

doi:10.19803/j.1672-8629.2022.06.17

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (6): 661-664.
DOI: 10.19803/j.1672-8629.2022.06.17

孟鲁司特致神经系统药品不良反应特点的分析

陈瑞家^1,2, 萨可佳¹, 曾晓芳^3,*

¹福建医科大学孟超肝胆医院,福建福州350001;
²福建医科大学附属第二医院,福建泉州 362000;
³福建医科大学附属协和医院,福建福州 350001

收稿日期:2020-07-07 出版日期:2022-06-15 发布日期:2022-06-13
通讯作者: ^* 曾晓芳,女,硕士,副主任药师,临床药学与医院药学。E-mail：zxfadr@126.com
作者简介:陈瑞家,女,硕士,主管药师,临床药学与医院药学。
基金资助:
福建省卫生计生科研人才培养项目（2017-2-31）; 福建省天然药物药理学重点实验室开放课题（FJNMP-201804）; 福建医科大学启航基金项目（2019QH1301）

Characteristics of Montelukast-induced adverse drug reactions in the nervous system

CHEN Ruijia^1,2, SA Kejia¹, ZENG Xiaofang^3,*

¹Department of Pharmacy, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou Fujian 350001,China;
²Department of Pharmacy, the Second Affiliated Hospital of Fujian Medical University, Quanzhou Fujian 362000, China;
³Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou Fujian 350001, China

Received:2020-07-07 Online:2022-06-15 Published:2022-06-13

摘要/Abstract

摘要： 目的探讨孟鲁司特引起神经及精神系统药品不良反应（adverse drug reaction, ADR）的临床特点及影响因素。方法检索中国知网、万方数据、维普网及PubMed数据库,检索时限均从建库至2020年2月29日。纳入孟鲁司特引起神经及精神系统ADR的病例报道及临床研究等,对患者年龄性别、用药剂量、服药后ADR出现时间及临床表现等信息进行分类整理和归纳。结果最终纳入符合的患者112例,年龄在1~86岁之间;ADR主要集中发生在14岁以下儿童;ADR出现时间最短为用药后30 min,最长为用药后2.5年,大多集中在服药后1周内;ADR症状主要表现为噩梦、睡眠障碍、攻击性、焦虑等。结论孟鲁司特导致的神经及精神系统ADR在儿童中更常见,医师需根据患者情况评估风险及获益,同时警惕可能的自杀风险。

关键词: 孟鲁司特, 药品不良反应, 神经及精神系统, 自杀

Abstract: Objective To investigate the clinical characteristics and causes of neurological and mental adverse drug reaction (ADR) induced by montelukast. Methods Such databases as CNKI, Wanfang, VIP and PubMed were searched for related articles published from the inception of databases to February 29, 2020. Case reports and clinical studies on neurological adverse drug reactions (ADR) caused by montelukast were included. Such information as the gender and age of patients, dosage, the time adverse drug reactions in the nervous system occurred and clinical manifestations was classified and summarized. Results A total of 112 patients aged 1 to 86 were collected. ADR mostly occurred in children under 14 years old. The time of intervals ranged from 30 minutes after medication to 2.5 years, and most of them occurred within one week of medication. The main symptoms of ADR were nightmares, sleep disorders, aggressiveness and anxiety. Conclusion Neurologic and mental ADR caused by montelukast are more common in children, and physicians should weigh the potential risks and benefits based on the patient’s condition while remaining alert to the possible risk of suicide.

Key words: montelukast, adverse drug reactions, the nervous and mental system, suicide

中图分类号:

R994.1

陈瑞家, 萨可佳, 曾晓芳. 孟鲁司特致神经系统药品不良反应特点的分析[J]. 中国药物警戒, 2022, 19(6): 661-664.

CHEN Ruijia, SA Kejia, ZENG Xiaofang. Characteristics of Montelukast-induced adverse drug reactions in the nervous system[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 661-664.

参考文献

[1] CHEN XQ, JIN YY, TANG G, et al.New pharmacology(新编药物学)[M]. Beijing: People's Medical Publishing House, 2018: 531-532.
[2] WU LJ, XIAO GJ.Clinical trial of montelukast combined with budesonide in the treatment of children with cough variation asthma[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2016, 32(22): 2032-2034, 2038.
[3] HE YC.Two cases of adverse reactions were caused by montelukast sodium[J]. Chinese Journal of Clinical Pharmacy(中国临床药学杂志),2008,17(1): 54.
[4] ANANDAN N, IBITOYE F.Montelukast and worsening of hallucinations in paranoid schizophrenia[J]. Psychiatric Bulletin,2008,32(7): 276.
[5] WALLERSTEDT SM,BRUNLÖF G,SUNDSTRÖM A. et al. Montelukast and psychiatric disorders in children[J]. Pharmacoepidemiol Drug Saf, 2009, 8(9): 858-864.
[6] LI XY, ZHOU XY.A case of mental abnormality caused by montelukast sodium[J]. Herald of Medicine(医药导报), 2011, 30(1): 116.
[7] SKILLMAN KL, STUMPF JL.Montelukast-induced anxiety in two pediatric patients[J]. Pharmacotherapy, 2011, 31(5): 90e-95e.
[8] HU SP.Nursing care of 1 case of mental symptoms in children caused by oral Shunerning (montelukast)[J]. Chinese Journal of Misdiagnostics(中国误诊学杂志), 2012, 12(7): 1764.
[9] FEI WS.A case of mental disorder caused by montelukast sodium[J]. Chinese Journal of Coal Industry Medicine(中国煤炭工业医学杂志), 2012, 15(2): 313.
[10] PU ZX, LI YL.Excitement and attention deficit caused by Montelukast in 2 children[J]. Medical Journal of National Defending Forces in Southwest China(西南国防医药), 2012, 22(6): 604.
[11] ZHOU H, ZHANG RF.Pharmaceutical care of a patient with montelukast sodium - induced psychosis[J]. Practical Pharmacy And Clinical Remedies(实用药物与临床), 2012, 15(2): 95-96.
[12] BYRNE F, OLUWOLE B, WHYTE V, et al.Delayed Onset of Neuropsychiatric Effects Associated with Montelukast[J]. Ir J Psychol Med. 2012, 29(2): 125-127.
[13] CALLERO-VIERA A,INFANTE S,FUENTES-APARICIO V,et al.Neuropsychiatric reactions to montelukast[J]. Investig Allergol Clin Immunol, 2012, 22(6): 452-453
[14] CEREZA G, GARCIA DN, LAPORTEJR. Nightmares induced by montelukast in children and adults[J]. Eur Respir J, 2012, 40(6):1574-1575.
[15] KOCYIGIT A, GULCAN OB, YARAR F, et al.Hallucination development with montelukast in a child with asthma: case presentation[J]. Iran J Allergy Asthma Immunol, 2013, 12(4): 397-399.
[16] ALKHUJA S, GAZIZOV N, ALEXANDER ME.Sleeptalking! Sleepwalking! Side effects of montelukast[J]. Case Rep Pulmonol, 2013, 2013: 813786.
[17] WANG XB.A case of abnormal behavior caused by montelukast sodium chewable tablets in children[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2014, 34(10): 858.
[18] LI WJ, HUANG N, ZHU RF.Clinical analysis on psychiatric adverse effects caused by montelukast sodium in children[J]. Adverse Drug Reactions Journal(药物不良反应杂志),2014, (4): 205-208.
[19] IBARRA-BARRUETA O, PALACIOS-ZABALZAI, MORA-ATORRASAGASTI O, et al.Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events[J].Ann Pharmacother, 2014, 48(1): 145-148.
[20] TIAN JX,LI JX,YANG JY, et al.A case of mental disorder caused by montelukast sodium chewable tablets[J]. Journal of Aerospace Medicine(航空航天医学杂志), 2015, 26(7): 916-917.
[21] LI TZ.Analysis of cases of psychiatric symptoms induced by montelukast sodium in asthmatic children[C]. Institute of Hospital Management of National Health and Family Planning Commission.Proceedings of the Chinese Society of Clinical Pharmacy Annual Meeting in 2015 and the 11th China Clinical Pharmacists Forum(2015年中国临床药学学术年会暨第十一届中国临床药师论坛论文集), 2015: 1-3.
[22] WU T, LIN JX.A case report of abnormal night dream in children with pneumonia caused by montelukast sodium chewable tablets[J].Chinese Journal of Clinical Rational Drug Use(临床合理用药杂志), 2017,10(22): 3-5.
[23] LI M, YANG C, YUAN HJ.One case of mental disorders induced by montelukast sodium[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2018, 15(2): 121-123.
[24] ALDEA PA, GARCÍA-SÁIZ M, SANZ ÁE. Psychiatric disorders and montelukast in children: a disproportionality analysis of the VigiBase[J]. Drug Saf, 2016, 39(1): 69-78.
[25] PHILIP G, HUSTAD C, NOONAN G, et al.Reports of suicidality in clinical trials of montelukast[J]. J Allergy Clin Immunol, 2009, 124(4): 691-696.

孟鲁司特致神经系统药品不良反应特点的分析

Characteristics of Montelukast-induced adverse drug reactions in the nervous system

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.